OTC Watch

All stocks / BIXT

BIOXYTRAN, INC BIXT

Bioxytran (BIXT): shares outstanding up 29% in a year, a late 10-Q notice in November 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Late filingDilutionEstimated float OTCQBMassachusetts, USA
Live quote on OTC Markets

Market listing

Full name
BIOXYTRAN INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.biomax.com
Source: Stockwatch, 2026-11-17

News headlines

Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
2026-11-16 07:00 · News Release
Bioxytran Secures Attested Free Sale Certification for A-SUQAR(TM), Opening the Path to the UAE and Gulf Markets
2026-11-04 07:00 · News Release
Bioxytran Completes Production of Two Dietary Supplements: V-LO(TM) for Immune Health and A-SUQAR(TM) for Healthy Blood Sugar
2026-10-19 07:00 · News Release
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
2026-08-11 07:00 · News Release
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
2026-08-04 07:00 · News Release
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
2026-07-29 07:00 · News Release
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
2026-05-29 08:03 · News Release
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
2026-03-20 09:05 · News Release
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
2026-03-04 15:40 · News Release
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
2026-03-02 11:40 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($2,123,077)
What it means

It spends more than it earns

Under strain

The company lost $2.1 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$509,914
Net cash used in operating activities
($526,455)
What it means

The cash could run out soon

Under strain

It had $509,914 in the bank and used about $43,871 a month. At that pace the money lasts about 12 months unless it borrows or sells more shares.

The report says
Total assets
$658,552
Total liabilities
$3,249,894
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $658,552. Its debts and unpaid bills add up to $3.2 million. That is about $4.93 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Late filing2026-11-16

Filed NT 10-Q on 2026-11-16: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Dilution2026-08-14

Shares outstanding rose from 88,992,243 (2025-08-08) to 114,695,220 (2026-08-14), up 29%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-08-14

Estimated float about 84,776,152 shares as of 2026-08-14: 114,695,220 outstanding minus 29,919,068 held by 7 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-04-01

Filed NT 10-K on 2026-04-01: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-09-30
89.0M
2025-11-14
99.1M
2025-12-31
108.1M
2026-03-31
113.4M
2026-04-15
113.4M
2026-05-15
114.2M
2026-06-30
114.7M
2026-08-14
114.7M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 8-K8-K
2026-11-16 NT 10-QNT 10-Q
2026-11-05 8-K8-K
2026-08-14 10-Q10-Q
2026-08-11 8-K8-K
2026-05-15 10-Q10-Q
2026-04-15 10-K10-K
2026-04-01 NT 10-KNT 10-K
2026-03-20 8-K8-K
2026-03-13 8-K8-K
2026-03-02 8-K8-K
2026-02-17 8-K8-K

Common questions about BIXT

Does BIXT file reports with the SEC?

Yes. Bioxytran files with the SEC under company number 0001445815. The most recent filing we hold is a 8-K dated 2026-11-16.

Source record

How many BIXT shares are outstanding?

114,695,220 shares as of 2026-08-14, as reported to the SEC. That is up 29% from 88,992,243 on 2025-08-08.

Source record

Has BIXT filed reports late?

Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-Q on 2026-11-16. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Bioxytran?

Officers named in its insider filings: David Platt (CEO), Michael Sheikh (CCO) and Ola Soderquist (CFO).

Source record

Is Bioxytran making money?

The company lost $2.1 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record